

Maria Stamelou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7979866/publications.pdf>

Version: 2024-02-01

159
papers

10,762
citations

41258

49
h-index

40881

93
g-index

162
all docs

162
docs citations

162
times ranked

9809
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Glutathione and Prodromal Parkinson's Disease Probability. <i>Movement Disorders</i> , 2022, 37, 200-205.	2.2	10
2	Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study. <i>Journal of Nutritional Biochemistry</i> , 2022, 105, 108994.	1.9	6
3	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 72-74.	1.1	0
4	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
5	Frailty and Prodromal Parkinson's Disease: Results From the HELIAD Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 622-629.	1.7	16
6	REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. <i>Sleep</i> , 2021, 44, .	0.6	6
7	The "zig-zag" sign in progressive supranuclear palsy "The slowness of vertical saccades was the clue. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 6-7.	1.1	0
8	Expanding the Spectrum of <i>AP5Z1</i> -Related Hereditary Spastic Paraplegia (<i>HSP</i> / <i>SPG48</i>): A Multicenter Study on a Rare Disease. <i>Movement Disorders</i> , 2021, 36, 1034-1038.	2.2	9
9	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	2.2	22
10	Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 1-4.	1.1	9
11	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021, 28, 1901-1909.	1.7	21
12	Serum Uric Acid in <i>LRRK2</i> Related Parkinson's Disease: Longitudinal Data from the PPMI Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 633-640.	1.5	3
13	Late life psychotic features in prodromal Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 67-73.	1.1	5
14	Childhood-Onset Chorea Caused by a Recurrent De Novo <i>DRD2</i> Variant. <i>Movement Disorders</i> , 2021, 36, 1472-1473.	2.2	6
15	Commentary: Insulinoma-Induced Hypoglycemia with Generalized Chorea, Dystonia, and Ataxia: A Neurological Kaleidoscope. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S9-S10.	0.8	0
16	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. <i>Nature Reviews Neurology</i> , 2021, 17, 601-620.	4.9	41
17	Apathy: An underestimated feature in GBA and <i>LRRK2</i> non-manifesting mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 1-8.	1.1	8
18	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	2.2	13

#	ARTICLE	IF	CITATIONS
19	Association of the Polygenic Risk Score With the Probability of Prodromal Parkinson's Disease in Older Adults. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 739571.	1.4	6
20	Validation of the Movement Disorder Society Criteria for the Diagnosis of Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
21	Circulating Brain-Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 457-467.	2.2	43
22	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	1.1	8
23	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
24	Clinical Conditions Suggestive of Progressive Supranuclear Palsy Diagnostic Performance. <i>Movement Disorders</i> , 2020, 35, 2301-2313.	2.2	22
25	Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 121-140.	1.1	13
26	A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1802-1809.	2.2	15
27	DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 36-42.	1.1	5
28	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	2.2	31
29	The different syndromes in Parkinson's disease: an overview. , 2020, , 235-249.		0
30	LRP1: A Novel Mediator of Tau Uptake. <i>Movement Disorders</i> , 2020, 35, 1136-1136.	2.2	1
31	Tremor in motor neuron disease may be central rather than peripheral in origin. <i>European Journal of Neurology</i> , 2019, 26, 394.	1.7	5
32	Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1087-1088.	2.2	2
33	Motor function and the probability of prodromal Parkinson's disease in older adults. <i>Movement Disorders</i> , 2019, 34, 1345-1353.	2.2	16
34	One decade ago, one decade ahead in progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1284-1293.	2.2	12
35	Neuroprotection in multiple system atrophy: unresolved issues. <i>Lancet Neurology</i> , The, 2019, 18, 710-711.	4.9	0
36	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 105-112.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	4.9	70
38	Emerging drugs for progressive supranuclear palsy. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 83-92.	1.0	6
39	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73
40	Mitochondrial complex I NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy. <i>European Journal of Neurology</i> , 2019, 26, 1240-1243.	1.7	9
41	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
42	Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Neuroscience Letters</i> , 2019, 704, 112-115.	1.0	21
43	A special issue on childhood-onset movement disorders. <i>Movement Disorders</i> , 2019, 34, 595-597.	2.2	1
44	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. <i>Neurology</i> , 2019, 92, e2261-e2272.	1.5	34
45	How to approach a patient with parkinsonism – red flags for atypical parkinsonism. <i>International Review of Neurobiology</i> , 2019, 149, 1-34.	0.9	4
46	Classification of atypical parkinsonism per pathology versus phenotype. <i>International Review of Neurobiology</i> , 2019, 149, 37-47.	0.9	10
47	Genetic mimics of the non-genetic atypical parkinsonian disorders – the "atypical" atypical. <i>International Review of Neurobiology</i> , 2019, 149, 327-351.	0.9	8
48	Progressive supranuclear palsy. <i>International Review of Neurobiology</i> , 2019, 149, 49-86.	0.9	19
49	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	1.1	7
50	Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. <i>Neurobiology of Aging</i> , 2019, 75, 224.e1-224.e8.	1.5	16
51	Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 48-57.	2.2	134
52	Phenotypic Characteristics in GBA-Associated Parkinson's Disease: A Study in a Greek Population. <i>Journal of Parkinson's Disease</i> , 2018, 8, 101-105.	1.5	18
53	Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: what's in a phenotype?. <i>Journal of the Neurological Sciences</i> , 2018, 390, 84-86.	0.3	1
54	Intrafamilial variability in a polish family harbouring a frameshift THAP1 mutation. <i>Journal of the Neurological Sciences</i> , 2018, 388, 158.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Selective cognitive impairment and hyposmia in p.A53T <i>SNCA</i> PD vs typical PD. <i>Neurology</i> , 2018, 90, e864-e869.	1.5	28
56	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018, 33, 21-35.	2.2	79
57	Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. <i>Movement Disorders</i> , 2018, 33, 75-87.	2.2	918
58	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. <i>Neuroscience Letters</i> , 2018, 672, 145-149.	1.0	35
59	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
60	¹²³ I-FP-CIT SPECT [(123) I-2-β-carbomethoxy-β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1734-1739.	2.2	9
61	Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. <i>CNS Drugs</i> , 2018, 32, 827-837.	2.7	16
62	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	1.1	17
63	Is increased spinal nociception another hallmark for Parkinson's disease?. <i>Journal of Neurology</i> , 2017, 264, 570-575.	1.8	9
64	Manual MRI morphometry in Parkinsonian syndromes. <i>Movement Disorders</i> , 2017, 32, 778-782.	2.2	67
65	The Motor Syndrome of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 25-32.	0.9	23
66	Advances in the Clinical Differential Diagnosis of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 79-127.	0.9	4
67	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
68	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	2.2	179
69	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
70	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. <i>Movement Disorders</i> , 2017, 32, 842-852.	2.2	52
71	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 37-43.	1.1	67
72	<i>TMEM230</i> : How does it fit in the etiology and pathogenesis of Parkinson's disease?. <i>Movement Disorders</i> , 2017, 32, 1159-1162.	2.2	13

#	ARTICLE	IF	CITATIONS
73	Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 82-87.	1.1	27
74	“Atypical” atypical parkinsonism: Critical appraisal of a cohort. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 36-42.	1.1	12
75	Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. <i>Movement Disorders</i> , 2017, 32, 1620-1630.	2.2	18
76	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
77	Nonmotor Features in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2017, 134, 1285-1301.	0.9	21
78	Transducer-based evaluation of tremor. <i>Movement Disorders</i> , 2016, 31, 1327-1336.	2.2	64
79	Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. <i>Movement Disorders</i> , 2016, 31, 1226-1230.	2.2	134
80	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016, 23, 772-779.	1.7	12
81	Atypical parkinsonism “ new advances. <i>Current Opinion in Neurology</i> , 2016, 29, 480-485.	1.8	16
82	A Review of Treatment Options for Progressive Supranuclear Palsy. <i>CNS Drugs</i> , 2016, 30, 629-636.	2.7	36
83	The Discovery of Central Nervous System Lymphatic Vessels: The Missing Link That Closes the Circle of Brain Immunosurveillance. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 29-30.	0.8	1
84	Late-onset cerebellar ataxia: Do not forget Friedreich's. <i>Movement Disorders</i> , 2016, 31, 7-8.	2.2	3
85	Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. <i>Movement Disorders</i> , 2016, 31, 1506-1517.	2.2	120
86	Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage. <i>European Journal of Pain</i> , 2016, 20, 1223-1228.	1.4	15
87	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 742-747.	2.2	29
88	What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 319-323.	0.9	186
89	The clinical syndrome of dystonia with anarthria/aphonia. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 20-27.	1.1	10
90	Lower urinary tract dysfunction in patients with functional movement disorders. <i>Journal of the Neurological Sciences</i> , 2016, 361, 192-194.	0.3	12

#	ARTICLE	IF	CITATIONS
91	Interventions in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S93-S95.	1.1	14
92	Multiple system atrophy-mimicking conditions: Diagnostic challenges. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S12-S15.	1.1	28
93	Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 357-364.	0.8	39
94	Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Movement Disorders</i> , 2015, 30, 1830-1834.	2.2	53
95	Levodopaâ€Responsive Parkinsonism with Prominent Freezing and Abnormal <scp>Dopamine Transporter</scp> Scan Associated with <scp>SANDO</scp> Syndrome. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 304-307.	0.8	7
96	Nonmotor Symptoms in Dopaâ€Responsive Dystonia. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 347-356.	0.8	10
97	From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link. <i>Movement Disorders</i> , 2015, 30, 1871-1872.	2.2	2
98	Hâ€ABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations?. <i>Movement Disorders</i> , 2015, 30, 828-833.	2.2	117
99	Diseaseâ€Modifying Treatments for Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 3-5.	0.8	6
100	Clinical relevance of serum antibodies to extracellular<i>N</i>-methyl-d-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 708-713.	0.9	97
101	Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control. <i>Current Biology</i> , 2015, 25, 1707-1716.	1.8	272
102	Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 533-535.	1.1	6
103	<i>ADCY5</i> mutations are another cause of benign hereditary chorea. <i>Neurology</i> , 2015, 85, 80-88.	1.5	140
104	Mutations in HPCA Cause Autosomal-Recessive Primary Isolated Dystonia. <i>American Journal of Human Genetics</i> , 2015, 96, 657-665.	2.6	151
105	The role of cerebellum in patients with late onset cervical/segmental dystonia?â€Evidence from the clinic. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1317-1322.	1.1	57
106	The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1264-1268.	1.1	25
107	The clinical and genetic heterogeneity of paroxysmal dyskinesias. <i>Brain</i> , 2015, 138, 3567-3580.	3.7	129
108	Atypical Parkinsonism. <i>Neurologic Clinics</i> , 2015, 33, 39-56.	0.8	34

#	ARTICLE	IF	CITATIONS
109	All in the blink of an eye: new insight into cerebellar and brainstem function in <scp>DYT</scp>1 and <scp>DYT</scp>6 dystonia. <i>European Journal of Neurology</i> , 2015, 22, 762-767.	1.7	38
110	Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study. <i>Movement Disorders</i> , 2014, 29, 1820-1825.	2.2	62
111	The phenotypic spectrum of DYT24 due to ANO3 mutations. <i>Movement Disorders</i> , 2014, 29, 928-934.	2.2	161
112	The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. <i>Movement Disorders</i> , 2014, 29, 1758-1766.	2.2	286
113	Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. <i>Movement Disorders</i> , 2014, 29, 245-251.	2.2	43
114	The Clinical Syndrome of Paroxysmal Exercise-Induced Dystonia: Diagnostic Outcomes and an Algorithm. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 57-61.	0.8	100
115	Psychogenic paroxysmal movement disorders – Clinical features and diagnostic clues. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 41-46.	1.1	77
116	Commentary. <i>Movement Disorders</i> , 2014, 29, 310-310.	2.2	0
117	Susceptibility-weighted imaging changes suggesting brain iron accumulation in Huntington's disease: an epiphenomenon which causes diagnostic difficulty. <i>European Journal of Neurology</i> , 2014, 21, e16-7.	1.7	14
118	The entity of parkinsonism and associated lipomatosis. <i>Neurology</i> , 2014, 83, 1673-1674.	1.5	2
119	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. <i>Brain</i> , 2014, 137, 2480-2492.	3.7	169
120	The expanding universe of disorders of the basal ganglia. <i>Lancet</i> , The, 2014, 384, 523-531.	6.3	155
121	Facial tremor in dystonia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 924-925.	1.1	10
122	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013, 260, 1132-1135.	1.8	10
123	Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation. <i>Journal of Neurology</i> , 2013, 260, 656-660.	1.8	17
124	Dystonic opisthotonus: A –red flag– for neurodegeneration with brain iron accumulation syndromes?. <i>Movement Disorders</i> , 2013, 28, 1325-1329.	2.2	39
125	Markedly asymmetric presentation in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 901-905.	1.1	21
126	Commentary for –Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease–. <i>Movement Disorders</i> , 2013, 28, 293-294.	2.2	0

#	ARTICLE	IF	CITATIONS
127	Tremulous cervical dystonia is likely to be familial: Clinical characteristics of a large cohort. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 634-638.	1.1	27
128	Functional movement disorders are not uncommon in the elderly. <i>Movement Disorders</i> , 2013, 28, 540-543.	2.2	40
129	Familial psychogenic movement disorders. <i>Movement Disorders</i> , 2013, 28, 1295-1298.	2.2	31
130	“Atypical” atypical parkinsonism: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy” A diagnostic guide. <i>Movement Disorders</i> , 2013, 28, 1184-1199.	2.2	167
131	Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. <i>Neurology</i> , 2013, 81, 1148-1151.	1.5	65
132	LOWER URINARY TRACT SYMPTOMS IN FUNCTIONAL MOVEMENT DISORDERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.56-e2.	0.9	0
133	Atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2013, 26, 401-405.	1.8	49
134	The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 650-656.	0.9	141
135	Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. <i>Neurology</i> , 2012, 79, 435-441.	1.5	45
136	The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. <i>Brain</i> , 2012, 135, 1668-1681.	3.7	246
137	Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 606-608.	1.1	19
138	Dystonia with brain manganese accumulation resulting from <i>SLC30A10</i> mutations: A new treatable disorder. <i>Movement Disorders</i> , 2012, 27, 1317-1322.	2.2	104
139	THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. <i>Movement Disorders</i> , 2012, 27, 1290-1294.	2.2	126
140	Mutations in ANO3 Cause Dominant Craniocervical Dystonia: Ion Channel Implicated in Pathogenesis. <i>American Journal of Human Genetics</i> , 2012, 91, 1041-1050.	2.6	224
141	Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2012, 6, 88.	1.0	44
142	Treatment of Focal Dystonia. <i>Current Treatment Options in Neurology</i> , 2012, 14, 213-229.	0.7	28
143	Psychogenic palatal tremor may be underrecognized: Reappraisal of a large series of cases. <i>Movement Disorders</i> , 2012, 27, 1164-1168.	2.2	126
144	Dystonia in corticobasal degeneration: A review of the literature on 404 pathologically proven cases. <i>Movement Disorders</i> , 2012, 27, 696-702.	2.2	119

#	ARTICLE	IF	CITATIONS
145	A new treatable genetic disorder of manganese metabolism causing dystoniaâ€parkinsonism and cirrhosis: The â€œNewâ€Wilson's disease?. <i>Movement Disorders</i> , 2012, 27, 962-962.	2.2	9
146	The distinct movement disorder in antiâ€NMDA receptor encephalitis may be related to status dissociatus: A hypothesis. <i>Movement Disorders</i> , 2012, 27, 1360-1363.	2.2	46
147	Magnetic resonance imaging in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2011, 258, 549-558.	1.8	44
148	Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 901-905.	2.2	3
149	AFQ056 treatment of levodopaâ€induced dyskinesias: Results of 2 randomized controlled trials. <i>Movement Disorders</i> , 2011, 26, 1243-1250.	2.2	162
150	Patients with idiopathic rapidâ€eyeâ€movement sleep behavior disorder show normal gastric motility assessed by the ¹³ Câ€octanoate breath test. <i>Movement Disorders</i> , 2011, 26, 2559-2563.	2.2	26
151	Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	13.9	77
152	Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy. <i>Neurodegenerative Diseases</i> , 2011, 8, 438-446.	0.8	53
153	In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS. <i>Movement Disorders</i> , 2010, 25, 1232-1238.	2.2	70
154	Rational therapeutic approaches to progressive supranuclear palsy. <i>Brain</i> , 2010, 133, 1578-1590.	3.7	83
155	Nigrostriatal upregulation of 5â€HT _{2A} receptors correlates with motor dysfunction in progressive supranuclear palsy. <i>Movement Disorders</i> , 2009, 24, 1170-1175.	2.2	13
156	Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid stenosis and changes upon treatment. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2009, 22, 43-52.	1.1	19
157	<i>In vivo</i> Evidence for Cerebral Depletion in High-Energy Phosphates in Progressive Supranuclear Palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 861-870.	2.4	43
158	Shortâ€term effects of coenzyme Q ₁₀ in progressive supranuclear palsy: A randomized, placeboâ€controlled trial. <i>Movement Disorders</i> , 2008, 23, 942-949.	2.2	135
159	Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 151-166.	0.2	105